Advertisement

Topics

Alzheon Publishes New Analyses Showing Clinical Benefit of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer’s Disease; Clinical Effects Suggest Disease Modification and Align with Beta Amyloid Oligomer Formation

08:30 EDT 22 Jun 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Analyses from Phase 3 Studies Published in The Journal of the Prevention of Alzheimer’s Disease Show Strongest Clinical Benefit of Tramiprosate in APOE4/4 Homozygous Patients with Mild AD at Baseline Results ...

Other Sources for this Article

The Yates Network
Kathryn Morris, 845-635-9828
kathryn@theyatesnetwork.com

NEXT ARTICLE

More From BioPortfolio on "Alzheon Publishes New Analyses Showing Clinical Benefit of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer’s Disease; Clinical Effects Suggest Disease Modification and Align with Beta Amyloid Oligomer Formation"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Alzheimer's Disease
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase  'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...